Arrowhead Pharmaceuticals Reports Q2 Loss Amid Strong REDEMPLO Launch, Major Licensing Deal, and $930M Capital Raise

summarizeSummary

Arrowhead Pharmaceuticals reported a Q2 net loss but highlighted strong commercial momentum for REDEMPLO®, a significant licensing deal with Madrigal Pharmaceuticals, and the completion of a $930 million capital raise, substantially strengthening its balance sheet and pipeline.

check_boxKey Events

• Q2 Financial Results Show Net Loss

  The company reported a net loss of $(132.7) million for Q2 FY2026, a decrease from $370.4 million net income in Q2 FY2025, primarily due to increased research and development and general and administrative expenses.

• REDEMPLO® Commercial Launch Gaining Momentum

  The U.S. launch of REDEMPLO® (plozasiran) shows strong traction with over 400 prescriptions to date, representing 40% growth in the last four weeks, and an updated U.S. wholesale acquisition cost of $45,000 per patient per year.

• Major Licensing Agreement with Madrigal Pharmaceuticals

  Arrowhead entered an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, receiving a $25 million upfront payment and eligible for up to $975 million in development, regulatory, and sales milestones, plus tiered royalties.

• Completion of $930 Million Capital Raise

  The company confirmed the completion of two concurrent public offerings totaling $930 million, consisting of $700 million in 0.00% convertible senior notes and $230 million through the issuance of common stock, substantially increasing total cash resources to $1.78 billion.

auto_awesomeAnalysis

Arrowhead Pharmaceuticals reported a net loss for Q2 FY2026, a significant shift from profitability in the prior year, primarily due to increased operating expenses as the company invests in its pipeline and commercialization efforts. However, this filing details several highly positive developments that underpin the company's strategic growth. The commercial launch of REDEMPLO® is gaining strong momentum, with accelerating prescriptions and a premium pricing strategy. Furthermore, Arrowhead secured a substantial licensing agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, including a $25 million upfront payment and up to $975 million in potential milestones, validating its RNAi platform. The company also confirmed the completion of a $930 million capital raise through convertible notes and common stock, significantly bolstering its cash resources to $1.78 billion. This financial strengthening, coupled with broad pipeline advancements and successful commercialization efforts, provides a strong foundation for future growth. The stock is currently trading near its 52-week high, reflecting investor confidence in these strategic initiatives despite the reported quarterly loss.